RION Launches INTENT Biologics to Advance Late-Stage Clinical Exosome Therapies in Inflammation & Immunology; Appoints Industry Leader Suneet Varma as CEO RION, a clinical-stage regenerative medicine company recognized globally for its pioneering work in exosome-based therapeutics, has announced the formation…
JCR Pharmaceuticals Showcases Landmark Five-Year Clinical Data on Pabinafusp Alfa at ICIEM 2025, Reinforcing Transformative Potential for Patients with Hunter Syndrome and Expanding Pipeline of Brain-Penetrant Enzyme Replacement Therapies In early September 2025, the city of Kyoto, Japan, became the…
Tolerance Bio and ZipCode Bio Forge Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics In a landmark move that underscores the growing intersection of immunology and RNA-based medicine, Tolerance Bio, a young biopharmaceutical company dedicated to extending healthspan by preserving…
FDA Expands Approval of Takeda’s VONVENDI®, First Recombinant von Willebrand Factor Therapy, to Include Routine Prophylaxis for Adults and Children with von Willebrand Disease Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), a global biopharmaceutical leader with a longstanding commitment to advancing therapies…
Genentech Presents New Long-Term Data for Vabysmo in Wet AMD and PCV at Euretina Congress 2025 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced compelling new data from two important clinical studies evaluating Vabysmo®…
SCIEX Expands BioPhase 8800 Capabilities with Native Fluorescence Detection to Advance Protein-Based CE Assays At the 2025 CE Pharm conference, SCIEX, a global leader in life science analytical technologies, announced the launch of native fluorescence detection on its flagship BioPhase…
Octave Bioscience Secures $35.6 Million Series C Financing and $15.5 Million Loan to Accelerate Growth and Advance Precision Care in Neurology Octave Bioscience, Inc., a commercial-stage precision care company dedicated to transforming the management of neurodegenerative diseases, has announced a…
MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for patients and families affected by ultra-rare lysosomal storage disorders, MEDIPAL…
Neurotech Pharmaceuticals Strengthens Leadership with Appointment of Dr. Peter J. McDonnell to Board of Directors Neurotech Pharmaceuticals, Inc., a privately held biotechnology company pioneering transformative therapies for chronic eye diseases, today announced the appointment of Peter J. McDonnell, M.D., a…
CapVest to Acquire Majority Stake in STADA from Bain Capital and Cinven CapVest Partners LLP (“CapVest”), a global investment firm with a reputation for building essential businesses across healthcare, consumer, and services sectors, has announced that it has signed a…
Ostro Unveils Airmark to Transform Static Pharma Emails into Dynamic, Compliant Conversational AI Ostro, an AI-powered engagement platform already trusted by more than half of the top 20 global pharmaceutical companies, has announced the launch of Ostro Airmark—a first-of-its-kind solution…
DNAnexus Expands Leadership to Drive AI Innovation and Biopharma Growth DNAnexus, Inc., a leader in enterprise solutions for precision health data, has unveiled a series of strategic leadership appointments that underscore its commitment to advancing artificial intelligence (AI), data-driven healthcare,…